Status: Therapeutic Antibody Discovery

CGEN-15027 is a novel antibody drug conjugate (ADC) candidate discovered by Compugen. 
Initial experimental evaluation of CGEN -15027, including the prediction and validation of high expression levels of CGEN-15027 in lung, breast, ovarian, and pancreatic tumors as compared to normal tissues, strengthened its potential as a target for ADC therapy. In addition, the ability of an exemplary ADC to mediate potent killing of cancer cell lines expressing this protein was demonstrated using therapeutic antibodies for CGEN-15027. The expression and functional data provide further validation of the target, and suggest broad first-in-class clinical opportunities CGEN-15027 antibodies in treating multiple solid tumor types.